ストックスクリーナーアプリを入手
325.58
0.58%
1.89
アフターアワーズ：
325.58
前日終値:
$323.69
開ける：
$323.03
24時間の取引高:
158.54K
Relative Volume:
0.60
時価総額：
$9.06B
収益：
$2.58B
当期純損益:
$-778.69M
株価収益率:
-55.65
EPS:
-5.85
ネットキャッシュフロー:
$223.75M
1週間 パフォーマンス:
-7.04%
1か月 パフォーマンス:
-5.11%
6か月 パフォーマンス:
+12.48%
1年 パフォーマンス:
+6.34%
1日の値動き範囲:
$320.32
$326.45
1週間の範囲:
$306.42
$349.07
52週間の値動き範囲:
$262.12
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
BIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| BIO | 325.58 | 9.06B | 2.58B | -778.69M | 223.75M | -5.85 |
| ABT | 117.26 | 201.11B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 390.14 | 148.40B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 91.50 | 134.72B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 84.74 | 108.57B | 33.00B | 4.29B | 5.50B | 2.71 |
| EW | 70.38 | 41.51B | 6.60B | 4.16B | 490.10M | 2.34 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-01 | アップグレード | Citigroup | Neutral → Buy |
| 2024-08-28 | 開始されました | Wells Fargo | Equal Weight |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-04-03 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-12-07 | 開始されました | UBS | Buy |
| 2023-06-16 | 開始されました | Wells Fargo | Overweight |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-01-28 | 繰り返されました | Citigroup | Buy |
| 2020-01-08 | 開始されました | Wells Fargo | Overweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2018-10-17 | 開始されました | Goldman | Buy |
| 2018-09-20 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-02-16 | ダウングレード | CL King | Buy → Neutral |
| 2017-07-13 | 開始されました | Wells Fargo | Outperform |
| 2017-06-28 | アップグレード | Deutsche Bank | Hold → Buy |
| 2017-01-18 | 開始されました | Deutsche Bank | Hold |
| 2016-10-13 | 開始されました | CL King | Buy |
| 2015-05-06 | 繰り返されました | Jefferies | Buy |
| 2009-12-18 | 開始されました | Maxim Group | Buy |
| 2009-11-06 | 開始されました | Jefferies & Co | Buy |
| 2009-07-17 | 開始されました | Soleil | Buy |
| 2007-09-26 | 開始されました | Banc of America Sec | Buy |
| 2007-02-23 | ダウングレード | Robert W. Baird | Outperform → Neutral |
すべてを表示
Bio Rad Laboratories Inc (BIO) 最新ニュース
Global Life Science and Chemical Instruments Market Set to Reach USD 79.7 Billion by 2034, Projected to Grow at 5.3% CAGR | Future Market Insights, Inc. - GlobeNewswire Inc.
Thompson Siegel & Walmsley LLC Sells 83,227 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference - Business Wire
One Step RT-qPCR Kits Market Key Players AnalysisTakara Bio - openPR
Natixis Advisors LLC Increases Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Leukemia Screening Market Future Business Opportunities - openPR
Custom Antibody Services Market Report: Detailed Insights - openPR
Cell Signaling Market: Opportunities, Challenges, and Growth - openPR
Electrophoresis Reagents Market: Company Profiles, Segment - openPR
Hematology Testing Products Market Statistical Forecast - openPR
Biological Multiplex Assays Market to Witness Significant - openPR
IVD quality control Market Share, Trends, Top Players, Segments - openPR
Biochips Market Opportunities and Trends With Leading Key - openPR
DNA Extraction Kits Market Is Booming Worldwide 2024-2031 | - openPR
Cell Viability Assays Market Opportunities and Trends - openPR
Molecular Quality Controls Market Size Analysis and Regional - openPR
Protein Engineering Market Projected to Reach USD 7.39 Billion by 2032 with a CAGR of 14.72% - GlobeNewswire Inc.
Mawer Investment Management Ltd. Boosts Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Protein Chip Market Growth, Industry Development and Forecast - openPR
Genomic Biomarker Market 2024 Opportunity, Challenge, - openPR
Laboratory Mixer Market Strong Industry Growth, Business - openPR
Research Antibodies Market Report Outlines Revenue Share, SWOT - openPR
Genomic Biomarker Market Dynamics and Forecast Comprehensive - openPR
Bio-Rad Laboratories, Inc. (NYSE:BIO) Stake Lowered by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Sumitomo Mitsui Trust Group Inc. Trims Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Clinical Diagnostics Market to Reach $ 110.0 Billion by 2031 | - openPR
Multiplexed Diagnostics Market Share, Trends, Top Players, - openPR
Apoptosis Assays Market Analysis By Top KeyplayersMerck, - openPR
High-throughput Screening Technology Market Size and Regional An - News Channel Nebraska
Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock Holdings Boosted by Principal Financial Group Inc. - MarketBeat
Evaluation of a New Multimodal Anion Exchange Resin for Emerging Biotherapeutic Process Challenges - BioProcess Insider
Short Interest in Bio-Rad Laboratories, Inc. (NYSE:BIO) Declines By 20.8% - MarketBeat
Chromatography Systems Market Industry Detailed Exploration, - openPR
VAN ECK ASSOCIATES CORP's Strategic Acquisition in Bio-Rad Labor - GuruFocus.com
Chiral Chromatography Columns Market Overall Study Report - openPR
Dental Services Market Overall Study Report 2024-2032 | Agilent - openPR
Genomics Market Overall Study Report 2024-2032 | Agilent - openPR
SEC Form SC 13G filed by Bio-Rad Laboratories Inc. - Quantisnow
Entropy Technologies LP Acquires Shares of 4,200 Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
4,200 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Bought by Entropy Technologies LP - MarketBeat
Bio-Rad Demonstrates Leadership Position in the Oncology Market at Association for Molecular Pathology 2024 - Technology Networks
Protein A Resin Market Growth, Size, Trends, Shares, By Top - openPR
Brokerages Set Bio-Rad Laboratories, Inc. (NYSE:BIO) Target Price at $391.80 - MarketBeat
Lung Cancer Diagnostics Market Anticipated for Positive Growth - openPR
Biochips Market Is Booming Worldwide 2024-2031 | Illumina, - openPR
Bio-Rad Laboratories: This Undervalued Stock Offers Investors a Rare Combination - Morningstar
ICICI Prudential Asset Management Co Ltd Raises Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity? - Insider Monkey
PCR Systems Market Growth, Industry Development and Forecast - openPR
Thalassemia Testing Market Ready to Rise Sharply On Superior - openPR
Bio-Rad demonstrates leadership position in the oncology market at Association for Molecular Pathology 2024 - Cambridge Network
Bio Rad Laboratories Inc (BIO) 財務データ
収益
当期純利益
現金流量
EPS
1.66%
0.80%
大文字化:
|
ボリューム (24 時間):